Skip to main content

Table 1 Relationship between CDK11 p58 expression and clinicopathological features in breast cancer patients

From: CDK11p58inhibits ERα-positive breast cancer invasion by targeting integrin β3 via the repression of ERα signaling

Characteristics

CDK11p58

 

Low

High

n

x 2

p

Age(years)

   

7.024

0.008

 <50

27(8.1%)

78(31.5%)

105

  

 ≥50

18(7.3%)

125(50.4%)

143

  

Menopausal status

   

0.375

0.540

 Pre

29(11.6%)

122(48.8%)

151

  

 Post

16(6.4%)

83(33.2%)

99

  

Tumor size (cm)

   

0.939

0.333

2 cm

18(7.4%)

95(39.1%)

113

  

 >2 cm

27(11.1%)

103(42.4%)

130

  

Node status

   

6.312

0.012

 Negative

18(7.2%)

124(49.6%)

142

  

 Positive

27(10.8%)

81(32.4%)

108

  

ER status

   

4.065

0.044

 Negative

33(13.2)

117(46.8%)

150

  

 Positive

12(4.8%)

88(35.2)

100

  

HER-2 status

   

2.823

0.093

 Negative

22(8.8%)

128(51.2%)

150

  

 Positive

23(9.2%)

77(30.8)

100

  

Differentiation

   

1.456

0.228

 III

26(13.7%)

142(74.7%)

130

  

 III

14(7.4%)

49(25.8%)

60

  

TNM stage

   

1.567

0.211

 III

23(11%)

129(61.4%)

152

  

 III

13(6.2%)

45(21.4%)

58

  

Relapse

   

9.323

0.002

 No

29(11.8%)

179(72.8%)

208

  

 Yes

13(5.3%)

25(10.2%)

38

  

Metastasis

   

4.803

0.023

 No

26(10.6%)

159(64.6%)

185

  

 Yes

16(6.5%)

45(18.3%)

61

  
  1. Statistically significant p < 0.05 are indicated in bold. ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.